Atlanta Consulting Group Advisors LLC Acquires Shares of 24,054 Kenvue Inc. (NYSE:KVUE)

Atlanta Consulting Group Advisors LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) in the third quarter, HoldingsChannel.com reports. The fund acquired 24,054 shares of the company’s stock, valued at approximately $556,000.

Several other hedge funds have also modified their holdings of KVUE. Riverview Trust Co purchased a new position in shares of Kenvue during the 3rd quarter valued at approximately $30,000. Ashton Thomas Securities LLC acquired a new position in Kenvue during the third quarter worth $35,000. Deseret Mutual Benefit Administrators lifted its holdings in Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares in the last quarter. Studio Investment Management LLC increased its stake in shares of Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after purchasing an additional 845 shares in the last quarter. Finally, AlphaMark Advisors LLC acquired a new position in shares of Kenvue during the 3rd quarter worth about $77,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a report on Tuesday, September 24th. Bank of America boosted their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler raised their price objective on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Price Performance

Shares of KVUE stock opened at $23.82 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $45.67 billion, a PE ratio of 43.31, a price-to-earnings-growth ratio of 2.16 and a beta of 1.36. The firm’s 50-day moving average is $22.77 and its two-hundred day moving average is $20.70. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.13.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.31 EPS. Analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is presently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.